2aG4

2aG4 is a murine monoclonal antibody of the IgG2a isotype that specifically targets phosphatidylserine (PS), an anionic phospholipid typically sequestered on the inner leaflet of the plasma membrane in healthy cells. In the tumor microenvironment and on virally infected cells, PS becomes exposed on the outer leaflet, where it acts as a potent immunosuppressive signal. 2aG4 binds to exposed PS in a manner that requires the serum cofactor beta-2-glycoprotein I (beta2GPI). This binding facilitates the destruction of tumor vasculature through antibody-dependent cellular cytotoxicity (ADCC) and effectively blocks the immunosuppressive signaling of PS to myeloid cells, such as macrophages and myeloid-derived suppressor cells (MDSCs). By inhibiting these signals, 2aG4 promotes a shift from an immunosuppressive (M2-like) to an immunostimulatory (M1-like) tumor microenvironment, enhancing anti-tumor immunity. Developed by Peregrine Pharmaceuticals, 2aG4 served as the murine precursor and proof-of-concept molecule for the chimeric clinical candidate bavituximab.

Other names

m2aG4m-2aG4m 2aG4mouse anti-phosphatidylserine antibody